Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Inclusion Criteria: \- Patients must have histologically confirmed HNSCC from any primary site, except nasopharyngeal if World Health Organization (WHO) Type III (non-keratinizing and Epstein-Barr virus (EBV)-positive)). Eligible histologies include: * Basaloid, poorly differentiated, and undifferentiated carcinoma histologies. * Nasopharyngeal carcinoma, WHO Type I and II (keratinizing, non-EBV positive). * Paranasal sinus, lip and external auditory canal sites. * Squamous cell carcinoma of unknown primary, clearly related to the head and neck. Note: Documentation of primary site diagnosis must be submitted with the registration request. * Patients must have recurrent and/or metastatic disease, fulfilling at least one of the criteria defined below: * Incurable disease as assessed by surgical or radiation oncology; * Metastatic (M1) disease; * Persistent or progressive disease following curative-intent radiation, and not a candidate for surgical salvage due to incurability or morbidity. Note: Patients who decline radical surgery are eligible. * For patients with oropharyngeal primary site or unknown primary site only: Patients must have known tumoral HPV status (p16). (Acceptable standards include p16 immunohistochemistry (where a tumor is classified as p16-positive when showing diffuse nuclear and cytoplasmic staining in at least 70% of tumor cells) and/or assessment of HPV DNA.) Note: For these subjects, documentation of p16 status must be submitted with the registrati…